Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer.
about
Parenteral anticoagulation in ambulatory patients with cancerPrimary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapyVenous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer AnticoagulantsPrimary prevention and treatment of venous thromboembolic events in patients with gastrointestinal cancers - ReviewVenous thromboembolism and lung cancer: a reviewAnticoagulants in cancerVenous thromboembolism in cancer patients: an underestimated major health problemThe effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trialsThromboprophylaxis guidelines in cancer with a primary focus on ambulatory patients receiving chemotherapy: a review from the Southern Network on Adverse Reactions (SONAR)Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol.Evidence-based guidance on venous thromboembolism in patients with solid tumoursPrimary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.Primary venous thromboembolism prophylaxis in patients with solid tumors: a meta-analysisApproach to chemotherapy-associated thrombosis.Venous thrombosis and cancer: from mouse models to clinical trials.The prothrombotic activity of cancer cells in the circulationEarly venous thromboembolic events are associated with worse prognosis in patients with lung cancer.Primary venous thromboembolism prophylaxis in ambulatory cancer patients.Thromboembolic disease in cancer patients.Certoparin for the treatment and prevention of thrombosis: pharmacological profile and results from clinical studies.Clinical models and biochemical predictors of VTE in lung cancer.Low molecular weight heparin (LMWH) for primary thrombo-prophylaxis in patients with solid malignancies - systematic review and meta-analysis.Engineered nanoparticles: thrombotic events in cancer.Low-molecular-weight heparins and cancer: focus on antitumoral effect.Recent advances in anticoagulant drug delivery.Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: Focus on Drug Therapy.Effects of Long-Term Low-Molecular-Weight Heparin on Fractures and Bone Density in Non-Pregnant Adults: A Systematic Review With Meta-Analysis.Low molecular weight heparin and cancer survival: clinical trials and experimental mechanisms.Prophylaxis of venous thromboembolism in cancer patients.Safety and efficacy of primary thromboprophylaxis in cancer patients.Venous Thromboembolism in Patients Diagnosed With Lung Cancer.Incidence and Effect of Thromboembolic Events in Radical Cystectomy Patients Undergoing Preoperative Chemotherapy for Muscle-invasive Bladder Cancer.Characterisation and risk assessment of venous thromboembolism in gastrointestinal cancers.The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials: comment.Acute multiple arterial thrombosis after cisplatin in base of tongue carcinoma: case report.Cancer and Thrombotic Risk: The Platelet Paradigm.Parenteral anticoagulation in ambulatory patients with cancer.Venous thromboembolism prophylaxis for ambulatory cancer patients, can we do better?Management of cancer-associated disseminated intravascular coagulation: guidance from the SSC of the ISTH: comment.Primary thromboprophylaxis (PTP) in ambulatory patients with lung cancer receiving chemotherapy: A systematic review and meta-analysis of randomized controlled trials (RCTs).
P2860
Q22252972-8E1F1866-6E1D-4C28-86D0-7302451D73E4Q24194257-C1C0D111-18A2-4344-B63A-149CD4C24004Q26741697-CED0D174-FB8D-459C-BB1A-182351F1AB87Q26753853-1F9D7C04-808A-4C91-A048-E885AAFF9E0DQ26784184-5550F9B6-B362-4E0F-B8EF-6B7932D29EEBQ26825228-FC47FFB5-BFD7-4807-BA74-7EB0A99E71D1Q26852015-92699B19-26F9-4B10-B28D-2C965C56CD98Q26852293-B26A318B-5006-4C56-A985-09A167CC23CFQ26995284-9BE14C7C-0EDE-475B-A16A-D9CA940CB7DAQ31088061-14429395-151E-49E3-A1B4-4FDAFF036631Q33763946-5595594A-06F5-402E-B81D-3B001D309AF2Q34546366-D4312E0D-402F-4714-9C67-2A639BFA9C9BQ35594902-2E4F6A8D-94B2-4CE5-BCA8-E0FB6B869A32Q36304793-B1978425-7F63-4DB6-8662-24CB3FF533EFQ36636558-B9FA5C5A-7638-4E36-8AF5-7B1B46C27AD3Q37088087-EB304A76-D590-45B4-A6B8-C034B34ABC5DQ37304305-7A412448-C250-477F-A7DE-CA931EF311E9Q38079522-5D70C57F-B35E-4767-9854-71BA0BB2C13BQ38083556-B693836A-9229-487E-A921-B0311E1ED0DCQ38102045-4A0AEE27-4481-4E8D-BD93-29EA9D18A722Q38205701-97F14E17-9B23-4BD0-BFEF-270B639B4FF3Q38243883-8CE76BF0-E623-4F4C-8B93-167EE31C89FEQ38262939-25D14C84-45E8-4BD7-A552-6689A9553537Q38376242-304048A6-81B2-4E78-A2E8-B1D17B870ABEQ38649939-696C59D8-76C7-481A-8285-CDB768D45BACQ38686333-05471C9D-7539-48B3-AD00-FF1DE70EEE68Q38741507-C00AE3E4-8A4C-476C-84C2-D59790FFDDFAQ38749053-9B413D40-B752-41B0-86FC-B023F57168B7Q38794476-441F90E5-ED90-4637-A68D-8E8FA7CF0276Q38826115-1B60A813-78D4-4CA9-82CA-844FC2B17DFBQ38944457-A489E428-FC94-4523-88D2-BB90BEA8F0C5Q40060285-2C8831BD-C100-40B2-82F9-97F532C51189Q42126706-F32CEC53-5A47-4B63-BD6E-4D3222886F77Q43453398-D2F1DB82-9C14-41BB-BB9B-BADAE72DDBBDQ44240233-04BB8AF0-3D66-4130-AC12-B3584D372022Q44264785-B91ACFAC-15E2-4449-B9A0-283A2D63C0F0Q47551857-B6E22356-AFEF-425B-97AC-66A5D010A313Q48142233-C2ACB41B-AB18-454C-BB1D-DFCA7E2AD2C9Q48215822-498DAE8C-35AB-432B-9E4C-B87558AEFE01Q48288156-3D1C64F4-4C88-4D58-9B5D-EA66D670D1F3
P2860
Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Low-molecular-weight heparin v ...... r or stage III/IV lung cancer.
@ast
Low-molecular-weight heparin v ...... r or stage III/IV lung cancer.
@en
type
label
Low-molecular-weight heparin v ...... r or stage III/IV lung cancer.
@ast
Low-molecular-weight heparin v ...... r or stage III/IV lung cancer.
@en
prefLabel
Low-molecular-weight heparin v ...... r or stage III/IV lung cancer.
@ast
Low-molecular-weight heparin v ...... r or stage III/IV lung cancer.
@en
P2093
P2860
P356
P1476
Low-molecular-weight heparin v ...... r or stage III/IV lung cancer.
@en
P2093
Ajay K Kakkar
Bettina Kemkes-Matthes
David Heigener
Lothar Heilmann
Mathias Freund
Nima Melzer
Sylvia K Haas
TOPIC Investigators
P2860
P304
P356
10.1177/1076029611433769
P577
2012-01-23T00:00:00Z